The Statin Data Peter Attia Deleted
These notes were generated by AI and may contain inaccuracies.
Dr. Peter Attia is hiding a graph showing that statins, specifically atorvastatin, the most profitable drug in history grossing over $150 billion, slashes GLP-1 levels in a human controlled trial. In a response letter, Peter attempted to discredit this study but completely omitted its central graphic while cherry-picking other panels from the same figure showing total cholesterol and LDL reductions. Omitting the most important result is curation, not nuance or accuracy.
This is not a personal attack, not about personalities, data, and logic. Not manufacturing controversy. Responding directly and transparently to arguments Peter made publicly in response to my work. Goal is thoughtful, substantive content to build a healthier intellectual ecosystem around science, medicine, and social media. Abbreviated version; full letter linked below.
Peter responding to my work, a repeated pattern. Most recently, devoted newsletter to a paper published 2 years ago described as recent, after I covered it extensively (threads, IG posts, newsletters, videos) and tagged him. Paper jumped to top of Cell Metabolism's most read list post-coverage. Less than 2 weeks later, his response appeared; others noted the connection publicly.
Shortly before, Peter invoked lean mass hyper-responder phenotype, area of active debate where I and colleagues are spearheading research. Collaborated with Peter's past head of research Bob Kaplan; offered direct collaboration with Peter in Journal of Clinical Lipidology editorial, which he declined citing lack of credibility.
Cell Metabolism study: 40 people, statin or control. Statin group: 50% reduction in GLP-1 levels, worsening glycemic markers and insulin resistance. Peter omitted this graph but showed others from same figure on cholesterol/LDL reductions—cherry-picking.
Peter argued absolute GLP-1 reduction small compared to postprandial surge—biological category error. Conflating transient spikes with basal levels is problematic; by that logic, fasting insulin irrelevant despite post-carb rises—no serious scientist would endorse.
Never claimed study proves statins categorically harmful. Concern: data absent from conversations. 50% reduction in central metabolic hormone plus worsening glycemia not clinically irrelevant. Identifies mechanism for risk mitigation like targeted bile acid supplementation (inexpensive, available).
Atorvastatin (most profitable drug), statins (most profitable class), GLP-1 (central hormone, salient with weight loss drugs)—yet info rarely in discourse or doctor's offices. Dismissing is ignorance as prudence.
Truth 1: Absence of Evidence is Not Evidence of Absence
Clear metabolic effect: statins (esp. atorvastatin) slash GLP-1. Unknown: long-term clinical harm. For widely prescribed long-term med to tens of millions, burden on medicine to prove safety. Disclose in shared decision-making.
Check heart health library at staycuriousmetabolism.com for deep dives on cholesterol meds, heart health, supplements, trials.
Speaker doing self statin RCT with atorvastatin—stay tuned.
Truth 2: Incentive Structures Shape Data
Clinical research expensive; models favor large heterogeneous populations for broad prescription base. Precision medicine better for individuals, population-level more profitable. Explains neglected questions.
Next step: larger study to replicate, substratify patients for personalized prescribing. Incentives predict downplaying risks, accentuating benefits, favoring averages over variability—not conspiracy, business model outcome.
Truth 3: Failure to Disclose Risks Erodes Trust
Transparency builds trust, even with imperfect data. Peter's omission likely intentional. Patients on statins should be concerned about GLP-1 effects for informed consent. Doctors/scientists/communicators must surface data, not suppress.
New to space; shifted from academic medicine. Values authenticity in debate, enjoys challenges, good-faith stress-testing with differing views.
Examples of Engaging Opposites
Public conversations with Paul Saladino (carnivore MD) and Walter Willett (prominent plant-based researcher). Good relationships by approaching as people, not ideologies.
Time capsule for navigating incentives, personalities. Accountability: commit to authenticity, transparency, honesty, respect. Question to audience: Who do you want me to be? What values to demonstrate? Will you partner as teachers?
Thanks to diverse, thoughtful communities fueling enthusiasm for mTor, metabolic paradoxes. Native career opportunity at age 30. Audience shapes educator; spends time in comments for feedback. Rookie year of serious public work, multi-decade journey.
Keep Nick Norwitz in your library
Save the videos and channels worth coming back to, and find them again in one place.
